NCT01323673

Ethanol-Free Clobetasol Propionate Foam 0.05% (Olux-E Foam) vs Vehicle Foam in the Treatment of Chronic Hand Dermatitis.

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 125 (actual)
• Sponsor: Stiefel, a GSK Company · Industry
• Sex: All
• Age: 12 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine how clobetasol proprionate foam works against a placebo foam in the treatment of hand dermatitis.

Detailed description

Topical corticosteroids have anti-inflammatory, immunosuppressive and antiproliferative properties. Clobetasol propionate foam 0.05% (Olux-E), a Class 1 corticosteroid, is formulated in an ethanol free petrolatum base that provides the benefits of a super-potent corticosteroid combined with moisturizing ingredients in the treatment of corticosteroid responsive dermatoses. The current study is designed to show efficacy and safety in the treatment of moderate to severe chronic hand dermatitis.

Conditions

• Dermatitis, Chronic

Interventions

Type	Name	Description
DRUG	clobetasol propionate 0.05%	2 times a day, 14 total days study treatment
DRUG	Vehicle / Placebo	2 times a day, 14 total days of study treatment

Timeline

• Start date: 2010-11-15
• Primary completion: 2011-03-01
• Completion: 2011-03-29
• First posted: 2011-03-25
• Last updated: 2018-06-20
• Results posted: 2011-12-21

Locations

10 sites across 1 country: United States